FDA reviews Grail's multi-cancer test
GRILGRAL
Statements (5)
- Neutral
FDA advisers endorse the safety of Grail's cancer test
- Bullish
Grail stock soars 34% ahead of FDA review for multi-cancer blood test
- Neutral
FDA Panel will evaluate GRAIL's PMA application for multi-cancer early detection test on September 23
- Neutral
GRAIL is drawing fresh attention after regulators set a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi-cancer early detection blood test.
- Neutral
US FDA will hold advisory meeting to review Grail's multi-cancer test